I

    Innate Pharma (IPHA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.22
    -0.01 (-0.45%)

    Market Cap: $247.97M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    76%(13/17)
    Avg Surprise
    +8.97%
    Streak
    1 Q

    Upcoming Estimates

    Jun 30, 2026
    EPS Consensus$-0.09
    Range$-0.09 - $-0.09
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.09+0.0%
    60d ago$-0.08+10.9%
    30d ago$-0.08+10.9%
    7d ago$-0.08+10.9%
    Current$-0.09
    Revenue Consensus
    $8M
    Range$8M - $8M
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26EST
    		-$-0.09---
    Mar 26
    		$0.00N/A+100.00%Beat+100.0%
    Dec 25
    		$N/A$-0.14N/ABeat-
    Sep 25
    		$-0.14$-0.14-1.57%Miss-
    Jun 25
    		$-0.30N/AN/ABeat+3.2%
    Mar 25
    		$-0.30$-0.40+25.00%Beat-
    Dec 24
    		$-0.30$-0.40+25.00%Beat-160.4%
    Sep 24
    		$0.00$0.00N/ABeat-
    Jun 24
    		$-0.31$-0.38+19.42%Beat-1593.7%
    Mar 24
    		$0.00$0.00N/ABeat-
    Dec 23
    		$-0.12N/A+71.90%Beat-
    Sep 23
    		$0.00$0.00N/ABeat-
    Jun 23
    		$0.02N/A+114.64%Beat-
    Mar 23
    		$0.00$0.00N/ABeat+100.0%
    Dec 22
    		$0.00N/A+100.00%Beat+100.0%
    Sep 22
    		$0.00$0.00N/ABeat-
    Jun 22
    		$0.00N/A+100.00%Beat-
    Mar 22
    		$-0.16$-0.17+5.88%Beat+11.1%
    Dec 21
    		$-0.66$0.00N/AMiss-275.0%
    Sep 21
    		$0.00$0.00N/ABeat+100.0%
    Jun 21
    		$0.00$0.00N/ABeat+100.0%
    Mar 21
    		$-0.18$0.05-460.00%Miss-144.6%
    Dec 20
    		$-0.18$-0.09-95.56%Miss+2.2%
    Sep 20
    		$-0.09$-0.09+0.00%Beat-312.4%
    Jun 20
    		$-0.08$-0.08-3.38%Miss+6.4%
    Mar 20
    		$-0.07$0.00N/AMiss-
    Dec 19
    		$-0.18$-0.18+0.00%Beat-327.6%
    Sep 19
    		$0.04N/A+149.44%Beat+114.6%
    Jun 19
    		$-0.09$-0.09+1.78%Beat+83.5%
    Mar 19
    		$0.00$0.00N/ABeat-
    Sep 18
    		$0.08$0.00N/ABeat+116.0%
    Jun 18
    		$-0.30N/AN/ABeat-
    Dec 17
    		$-0.54N/AN/ABeat-278.9%
    Sep 17
    		$0.00$0.00N/ABeat-
    Jun 17
    		$-0.49N/AN/ABeat-
    Mar 17
    		$0.00$0.00N/ABeat-
    Dec 16
    		$0.30N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-2.14EV/EBITDA-6.94x
    Price/FCF-1.92xFCF Yield-52.11%
    Profitability
    Profit Margin0.00%Operating Margin-690.00%
    ROE-271.40%ROIC804.73%
    Financial Health
    Debt/Equity-0.41xInterest Coverage-18.17x
    Current Ratio1.27xQuick Ratio1.27x
    Trading Statistics
    Beta0.86Avg Volume388.48K
    52-Week High$2.7152-Week Low$1.17

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.19
    SMA 20$2.11
    SMA 50$1.92
    SMA 200$1.74
    EMA 10$2.19
    EMA 20$2.12
    EMA 50$1.97
    EMA 200$1.82

    MACD

    Line: 0.10Signal: 0.10Hist: -0.00

    ADX

    ADX: 23.7+DI: 30.5-DI: 19.5

    Aroon & PSAR

    Aroon Up56.0
    Aroon Down36.0
    PSAR$2.19

    Bollinger Bands

    Upper Band$2.58
    Lower Band$1.64
    %B Position4481%(Upper)
    Band Width0.61

    RSI (14-Day)

    Neutral
    56.2

    Momentum Oscillators

    Stoch %K33.2
    Stoch %D43.6
    Williams %R-73.1
    ROC (10d)1.8%
    Momentum0.04
    CCI (20d)42.8
    MFI (14d)58.2

    Volatility Measures

    ATR (14d)$0.15(6.9%)
    StdDev (20d)0.24
    Hist Vol137.5%(High)

    Volume Flow

    VWAP$2.24
    OBV19.5M
    AD Line1.7M
    CMF (20d)-0.304

    Volume Metrics

    Avg Vol (20d)425.7K
    Vol Ratio0.0x(Low)
    VWMA (20d)$2.23

    Pivot Points

    R3$2.29
    R2$2.28
    R1$2.25
    Pivot Point$2.24
    S1$2.21
    S2$2.20
    S3$2.17

    Advanced Oscillators

    TSI15.08
    Ultimate Osc45.3
    KST225.96

    Financial Data

    QuarterMar 2026Dec 2025Jun 2025Mar 2025Dec 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total Revenue$-2,073,000$-2,073,000$4.86M$276,000$276,000$12.35M$16.56M$21.44M$10.72M$35.34M$20.10M$8.31M
    Cost of RevenueN/AN/A$20.52M$-29,076,000$-29,076,000$29.08M$24.57M$24.57M$12.28M$15.73M$15.73M$13.35M
    Gross Profit$18.45M$18.45M$-15,660,000$29.35M$29.35M$-16,731,000$-3,126,000$-3,126,000$-1,563,000$19.62M$4.37M$-5,044,501
    Operating Expenses$46.45M$46.45M$9.77M$54.61M$54.61M$9.58M$9.14M$8.06M$4.03M$36.95M$3.83M$34.73M
    R&D$22.93M$22.93M$20.52M$22.90M$22.90M$29.08M$24.57M$24.57M$12.28M$28.41M$15.73M$25.16M
    SG&A$1.39M$1.39M$9.61M$2.52M$2.35M$9.42M$8.97M$8.97M$4.49M$4.50M$4.50M$5.07M
    Operating Income$-27,998,000$-27,998,000$-25,427,000$-25,262,000$-25,262,000$-26,313,000$-7,416,000$-12,270,000$-6,135,000$-5,253,000$-199,500$-28,804,000
    Interest Income$0$0$0$0$101,000$0$0$0$0$0$0$0
    Interest Expense$2.87M$2.87M$250,110$34,000$34,000$600,000$3.02M$3.02M$0$324,000$94,000$94,000
    Income Before Tax$-27,833,000$-27,833,000$-21,344,000$-24,707,000$-24,707,000$-24,764,000$-4,434,000$-9,288,000$-4,644,000$-3,136,000$859,000$-68,113,000
    Income Tax Expense$-2,993,675$-2,993,675$0$0$0$0$-9,750,000$-9,750,000$0$-4,854,000$-3,765,000$-3,765,000
    Net Income$-27,626,979$-27,626,979$-21,344,000$-24,707,000$-24,707,000$-24,764,000$-9,288,000$-9,288,000$-4,644,000$1.72M$859,000$-64,406,000
    EBITDA$-30,705,025$-30,705,025$-25,061,000$-21,348,000$-21,348,000$-25,563,000$-10,396,000$-10,396,000$-5,198,000$832,000$1.41M$-10,077,000
    EBIT$-31,377,013$-31,377,013$-25,427,000$-22,592,000$-22,592,000$-26,313,000$-12,270,000$-12,270,000$-6,135,000$-2,813,000$-199,500$-12,459,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IPHA

    News

    Innate Pharma SA (XTER:IDD) Stock Price & 30 Year Financial Data

    This article provides 30-year financial data for Innate Pharma SA (XTER:IDD), including stock price, market capitalization, enterprise value, and various growth rates. It details annual and quarterly financial metrics and offers tools for financial analysis and data export. The platform, GuruFocus, also presents a range of screeners, guru trades, insider trading information, and market indicators.

    GuruFocus•8/23/26•
    Neutral

    Innate Pharma SA (XTER:IDD) Valuation: Significantly Overvalued

    GuruFocus.com has assessed Innate Pharma SA (XTER:IDD) and determined that its stock is significantly overvalued. The company's current share price of €1.78 is substantially higher than its calculated GF Value of €0.12. Furthermore, a correlation analysis revealed no significant relationship between Innate Pharma SA's stock price and key financial metrics such as revenue per share, book value per share, EPS without NRI, and operating cash flow per share.

    GuruFocus•8/23/26•
    Neutral

    Innate Pharma (IPHA) sells 17.6M shares to fund ADCs, cash runway to Q3 2026

    Innate Pharma (IPHA) has successfully raised approximately €30.0 million in gross proceeds, or €27.6 million net, through a private placement of 17,647,059 new ordinary shares at €1.70 each. The funds are primarily intended to support the clinical development of its Nectin-4 ADC IPH4502 and advance its preclinical ADC portfolio. This financing extends the company's cash runway until the end of Q3 2026, and with an anticipated $75 million upfront payment from a strategic partnership with Sobi, the runway is expected to stretch through Q1 2028.

    Stock Titan•8/19/26•
    Somewhat-Bearish

    Innate Pharma SA (HAM:IDD) Valuation: Significantly Overvalued

    GuruFocus.com has assessed Innate Pharma SA (HAM:IDD) and determined that its stock is significantly overvalued. With a current share price of €1.896 against a GF Value of €0.14, the proprietary algorithm indicates a substantial discrepancy. Furthermore, a correlation analysis revealed no significant link between the stock price and key financial metrics such as revenue per share, book value per share, EPS without NRI, or operating cash flow per share.

    GuruFocus•8/16/26•
    Neutral

    Innate Pharma Secures €30M, Extends Cash Runway Into 2028

    Innate Pharma has raised €30 million in equity financing, extending its cash runway through Q1 2028, especially when combined with an anticipated €75 million upfront payment from its partnership with Sobi. This funding will support the development of lacutamab and IPH4502 programs, along with its preclinical antibody-drug conjugate (ADC) portfolio. The company is also awaiting primary-endpoint data from the PACIFIC-9 study for monalizumab, which could represent a significant future value source.

    TradingView•8/14/26•
    Bullish

    Frequently Asked Questions About IPHA

    Does IPHA pay dividends?
    Innate Pharma (IPHA) does not currently pay a regular dividend.
    What is IPHA's market cap?
    Innate Pharma (IPHA) has a market capitalization of $247.97M with a current stock price of $2.22.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In